PT - JOURNAL ARTICLE AU - El-Hay, Tal AU - Karavani, Ehud AU - Peretz, Asaf AU - Ninio, Matan AU - Ravid, Sivan AU - Chorev, Michal AU - Rosen-Zvi, Michal AU - Patalon, Tal AU - Shimoni, Yishai AU - Jain, Anil TI - Trends in clinical characteristics and associations of severe non-respiratory events related to SARS-CoV-2 AID - 10.1101/2021.03.24.21251900 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.24.21251900 4099 - http://medrxiv.org/content/early/2021/03/26/2021.03.24.21251900.short 4100 - http://medrxiv.org/content/early/2021/03/26/2021.03.24.21251900.full AB - Background The 2019 novel coronavirus (SARS-CoV-2) is reported to result in both respiratory and non-respiratory severe health outcomes, but quantitative assessment of the risk – while adjusting for underlying risk driven by comorbidities – is not yet established.Methods A retrospective observational study using electronic health records of 9,344,021 individuals across the U.S. with at-least 1 year of clinical history and followed up throughout 2020.Results 131,329 individuals were associated with SARS-CoV-2 infection by January 6, 2021 in three distinct surges. While the age and number of preexisting conditions had decreased throughout the pandemic, the characteristics of those who experienced severe health events did not.During the second surge, between June 7 and November 18, 2020, 425,988 individuals in the base cohort were admitted to emergency rooms or hospitals. Among them, 15,486 were detected with SAR-CoV-2 within few days of admission. Significant adjusted odds ratios were observed between SARS-CoV-2 infection and the following severe health events: respiratory (4.38, 95% confidence interval 4.16– 4.62), bacterial pneumonia (3.25, 2.76–3.83), sepsis (1.71, 1.53–1.91), renal (1.69, 1.57–1.83), hematologic/immune (1.32, 1.20–1.45), neurological (1.23, 1.09–1.38).Conclusions SARS-CoV-2 infection among hospitalized patients is associated with non-negligible increased risk of severe events including multiple non-respiratory ones. These associations, which complement recent studies, are persistent even after accounting for sources of selection and confounding bias, increasing the confidence they are not spurious.Competing Interest StatementTEH has nothing to disclose. EK has nothing to disclose. AP has nothing to disclose. MN has nothing to disclose. SR has nothing to disclose. MC has nothing to disclose. MRZ has nothing to disclose. TP has nothing to disclose. YS has nothing to disclose. AJ reports personal fees from IBM Corporation, outside the submitted work.Funding StatementNo external funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is a retrospective analysis of data extracted from anonymized electronic health records. Therefore, it has been exempt from submission to Ethics Committee by Prof. Adi Leiba, head of Helsinki Committee at Assuta Ashdod hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting the findings of this study are available from IBM Explorys but were used under license for the current study and restrictions may apply to their availability.